Coherus BioSciences (NYSE:CHRS) – Junshi Biosciences, Coherus Receive FDA Breakthrough Therapy Status for toripalimab in Head and Neck Cancer

Coherus BioSciences (NYSE:CHRS) – Junshi Biosciences, Coherus Receive FDA Breakthrough Therapy Status for toripalimab in Head and Neck Cancer

  • The FDA has awarded Breakthrough Therapy Designation (BTD) to Shanghai Junshi Biosciences Co LtdCoherus BioSciences Inc’s (NASDAQ: CHRS) toripalimab for recurrent or metastatic nasopharyngeal cancer (NPC).
  • NPC is a rare tumor of the head and neck region.
  • The designation includes toripalimab in combination with chemotherapy (gemcitabine and cisplatin) for the first-line treatment of NPC.
  • The FDA had previously awarded BTD for toripalimab monotherapy for patients with relapsed or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
  • Price promotion: CHRS shares are up 7.04% to $14.30 during the premarket session on Thursday’s last check.
  • Related Content: Benzinga’s Full FDA calendar.

Leave a Comment

x